Literature DB >> 31515121

Early postoperative stimulated serum thyroglobulin quantifies risk of recurrence in papillary thyroid cancer.

Jayani Jayasekara1, Pascal Jonker1, Jia Feng Lin1, Anton F Engelsman1, Man-Shun Wong1, Schelto Kruijff1, Ahmad Aniss1, Diana Learoyd2, Roderick Clifton Bligh2, Anthony Glover1, Leigh Delbridge1, Stan Sidhu1, Mark Sywak3.   

Abstract

BACKGROUND: Postoperative follow-up of papillary thyroid cancer includes serial serum thyroglobulin levels. This study aimed to determine whether stimulated thyroglobulin levels measured in the early postoperative period can accurately quantify the risk of recurrence in papillary thyroid cancer.
METHODS: We undertook a cohort study of patients who underwent total thyroidectomy for papillary thyroid cancer ≥10 mm in the period 2000 to 2016 with complete biochemical data. All patients had a postoperative stimulated thyroglobulin measured within 3 months after total thyroidectomy. Structural recurrence was defined as disease detected on imaging and confirmed on histology. Biochemical disease was defined as patients with stimulated serum thyroglobulin ≥1 ng/mL with no evidence of structural disease.
RESULTS: This study included 502 patients with a mean age of 50 years and median tumor diameter of 20 mm. Median follow-up was 18 months. Stimulated postoperative thyroglobulin was measured before radioiodine-ablation and was categorized into 3 groups: (1) 219 (44%) patients had thyroglobulin <1 ng/mL; (2) 55 (11%) had 1ng/mL ≤ thyroglobulin <2 ng/mL; and (3) 228 (45%) had thyroglobulin ≥2 ng/mL. The structural recurrence rate for each group was 5%, 2%, and 30%, respectively (P < .0001).
CONCLUSION: In patients undergoing total thyroidectomy for papillary thyroid cancer, early postoperative stimulated thyroglobulin accurately quantifies the risk of structural disease recurrence. Crown
Copyright © 2019. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31515121     DOI: 10.1016/j.surg.2019.06.048

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  3 in total

1.  Value of stimulated pre-ablation thyroglobulin as a prognostic marker in patients with differentiated thyroid carcinoma treated with radioiodine.

Authors:  Giulliana Nóbrega; Milena Cavalcanti; Verônica Leite; Lúcio Vilar; Simone Cristina Soares Brandão
Journal:  Endocrine       Date:  2022-03-02       Impact factor: 3.925

2.  New approach of prediction of recurrence in thyroid cancer patients using machine learning.

Authors:  Soo Young Kim; Young-Il Kim; Hee Jun Kim; Hojin Chang; Seok-Mo Kim; Yong Sang Lee; Soon-Sun Kwon; Hyunjung Shin; Hang-Seok Chang; Cheong Soo Park
Journal:  Medicine (Baltimore)       Date:  2021-10-22       Impact factor: 1.817

Review 3.  The Role of Thyroglobulin in Preoperative and Postoperative Evaluation of Patients With Differentiated Thyroid Cancer.

Authors:  Sha Li; Chutong Ren; Yi Gong; Fei Ye; Yulong Tang; Jiangyue Xu; Can Guo; Jiangsheng Huang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-02       Impact factor: 6.055

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.